Samsung Biologics Introduces Latest Production Plant
P4 is partially operational in under two years
Samsung Biologics, a contract development and manufacturing organization (CDMO), revealed that its South Korea-based Plant 4 has officially begun good manufacturing practice (GMP) operations. Plant 4’s partial operations come just 23 months after construction commenced in November 2020, adding fresh production capacity of 60,000 liters. It will have a total capacity of 240,000 liters when it becomes fully completed in the first half of 2023.
According to the CDMO, the new plant is expected to help the company maximize operational efficiency, alongside further improving its scale up development and manufacturing capability. Once P4 is completed, Samsung Biologics will have a total capacity of 604,000 liters at Bio Campus I.
“At the P4 groundbreaking ceremony in late 2020, we committed to have the plant up and running by October this year. I am very proud to have delivered on that promise, and confident that this will further solidify our position as a global leading CDMO,” comments John Rim, CEO and president of Samsung Biologics. “As a trusted partner, we will continue investing domestically and globally to support our clients worldwide and provide expanded services.”
Looking ahead, the CDMO has purchased additional land for Bio Campus II, which will house Plants 5 through 8, as well as an Open Innovation Center. Construction is set to begin later this year, and the lot itself is expected to be 30% larger in size compared to Bio Campus I.
